Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.
The Pharmaceutical Benefits Scheme (PBS) listing for enzalutamide has recently been expanded. Enzalutamide is an oral inhibitor of androgen receptor signalling. It is now subsidised for the treatment of metastatic hormone-sensitive prostate cancer, in…
Read more
The darolutamide product information has recently been updated to include information about hepatotoxicity. Darolutamide is a non-steroidal androgen receptor antagonist used in the treatment of prostate cancer. In the ARAMIS trial involving 1508 men…
Read more
Patiromer is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of chronic hyperkalaemia. Criteria to qualify for PBS-subsidised treatment include: Stage 3-4 chronic kidney disease; Condition not adequately controlled by a…
Read more
The Therapeutic Goods Administration (TGA) has issued a safety advisory regarding an association between liver injury and medicines containing turmeric or curcumin. The TGA has received 18 reports of liver problems in people taking…
Read more
Eptinezumab has been added to the Pharmaceutical Benefits Scheme (PBS) for the preventive treatment of chronic migraine in adults. To qualify for PBS subsidy, patients must average 15 or more headache days per month…
Read more
A new indication has been added to the product information for baricitinib. In addition to rheumatoid arthritis and atopic dermatitis, baricitinib is now also approved for the treatment of severe alopecia areata. This therapy…
Read more
